Cablivi (caplacizumab)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- caplacizumab
- Company
- Ablynx NV
- Status
- Authorised
- Therapeutic area
- Purpura, Thrombotic Thrombocytopenic
- CHMP opinion
- Thu 31 May 2018
- EU approval
- Thu 30 Aug 2018
- Designations
- Orphan
- Application
- EMEA/H/C/004426
- ATC
- B01A
- Official record
- www.ema.europa.eu
Indication
Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
Regulatory milestones
No milestones recorded in the last year.
Follow Cablivi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.